Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study

Chen, Yu-Lan1,2; Hu, Chao-Jun3,4; Peng, Lin-Yi3,4; Wang, Chu-Han3,4; Zhao, Yan3,4; Zhang, Wen3,4; Liu, Dong-Zhou1,2

2021-10-01

10.1002/jcla.24045

JOURNAL OF CLINICAL LABORATORY ANALYSIS   影响因子和分区

0887-8013

1098-2825

Background Previous studies have demonstrated that Ro60 and Ro52 have different clinical implications, and anti-Ro52 antibodies are an independent serum marker of systemic autoimmune diseases, including Sjogren's syndrome. Many different assays have been adopted to detect anti-Sjogren's syndrome antigen A (SSA)/Ro antibodies, while to date no specific approach has been recommended as optimal for anti-SSA/Ro antibody testing. Herein, we performed a multi-center study to explore the current clinical utility of different strategies for anti-SSA/Ro antibody testing in China. Methods Twenty-one tertiary care centers were included in this questionnaire-based study. The self-administered questionnaire mainly includes testing methods for anti-SSA/Ro antibodies, reporting system of results, and interpretation of results by clinicians. Results Six different methods were applied to detect anti-SSA/Ro antibodies in the 21 centers. Line immunoassay (eight different commercial kits) was the most frequently adopted method (21/21, 100%), with different cutoff values and strategies for intensity stratification. There were two reporting systems: One was reported as "anti-SSA antibodies" and "anti-Ro52 antibodies" (12/21, 57%), while the other was "anti-SSA/Ro60 antibodies" and "anti-SSA/Ro52 antibodies" (9/21, 43%). Notably, six centers (29%) considered either positive anti-Ro60 or anti-Ro52 antibodies as positive anti-SSA antibodies, all of which adopted the latter reporting system. Conclusion Significant variabilities existed among anti-SSA/Ro assays. Nearly 30% of centers misinterpreted the definition of positive anti-SSA antibodies, which may be attributed to the confusing reporting systems of line immunoassay. Therefore, we advocate standardization of the nomenclature of anti-SSA/Ro antibodies, changing the "anti-SSA/Ro52" label in favor of the "anti-Ro52" antibodies for a clear designation.

anti-Ro52 antibodies anti-Ro60 antibodies anti-SSA Ro antibodies detection assay reporting system Sjogren's syndrome

SCI

英语

通讯

Shenzhen Science and Technology Plan Program[JCYJ20190807144418845] ; Sanming Project of Medicine in Shenzhen[SYJY201901] ; National Natural Science Foundation of China[81971464,81771780] ; National Key Research and Development Program of China[2019YFC0840603] ; CAMS Initiative for Innovative Medicine[2017-I2M-3-001]

Medical Laboratory Technology

Medical Laboratory Technology

WOS:000709510600001

WILEY

CLINICAL MEDICINE

Web of Science

1.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Rheumatol & Immunol, Jinan, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, 1017 Dongmen North Rd, Shenzhen 518021, Peoples R China
3.Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Key Lab Rheumatol & Clin Immunol, Dept Rheumatol,Minist Educ, Beijing, Peoples R China
4.Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China

Chen, Yu-Lan,Hu, Chao-Jun,Peng, Lin-Yi,et al. Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study[J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS,2021.

Chen, Yu-Lan.,Hu, Chao-Jun.,Peng, Lin-Yi.,Wang, Chu-Han.,Zhao, Yan.,...&Liu, Dong-Zhou.(2021).Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study.JOURNAL OF CLINICAL LABORATORY ANALYSIS.

Chen, Yu-Lan,et al."Current state of technologies and recognition of anti-SSA/Ro antibodies in China: A multi-center study".JOURNAL OF CLINICAL LABORATORY ANALYSIS (2021).